quetiapine liquid oral suspension / OWP Pharma - LARVOL DELTA

Quetiapine Oral Solution in Alzheimer's Disease: Efficacy and Dosage Insights from a Real-World Retrospective Study. (PubMed, J Alzheimers Dis) - "We demonstrated our clinical experience of the use of quetiapine oral solution in AD patients with NPS. Our results showed that quetiapine oral solution treatment significantly improved these symptoms at a relatively low dose."

Journal • Real-world • Real-world evidence • Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • Psychiatry

The stability of quetiapine oral suspension compounded from commercially available tablets. (PubMed, PLoS One) - "In addition to the total drug in the suspensions, the dissolved drug in the vehicles was also measured during the stability testing and evaluated as a stability parameter. Overall, QF suspension prepared in Ora-Blend was preferable, demonstrating a superior 60-day stability at both room temperature and refrigerated storage."

Journal • CNS Disorders • Pediatrics

Treatment options for Parkinson’s disease psychosis (YouTube) - "Stuart Isaacson, MD...gives an overview of the current treatment strategies available to treat Parkinson's disease (PD) psychosis. PD psychosis is a common non-motor symptom of PD characterized by frequent and severe hallucinations or delusions. To treat PD psychosis, it is sometimes necessary to decrease the medications used to control the motor symptoms. Moreover, the treatment is limited by only three available medications (clozapine, quetiapine, pimavanserin) that do not worsen the motor manifestations of PD but have low efficacy. Dr Isaacson also comments on a proof of concept study of a new type of anti-psychotic with the potential to improve treatment. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting."

Interview • Video

OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder (GlobeNewswire) - "OWP announced today that it has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate."

IND • CNS Disorders • Schizophrenia